David McMillion, MD
Family Medicine · Huntsville, ALNPI 1134339880
Payments from drug & device makers
Across 716 payments — averaging $11.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Boehringer Ingelheim$1K
- Takeda Pharmaceuticals U.S.A., Inc.$762
- Lilly USA, LLC$725
- Amarin Pharma, Inc.$619
- Amgen$566
- plus $2K from 31 others
What the payments were for
- Food & beverage$7,99798%
- Education$1462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 294 | $2,318 |
| Boehringer Ingelheim | 74 | $1,006 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $762 |
| Lilly USA, LLC | 60 | $725 |
| Amarin Pharma, Inc. | 77 | $619 |
| Amgen(2 entities) | 39 | $566 |
| AbbVie(2 entities) | 38 | $456 |
| AstraZeneca | 19 | $315 |
| Pfizer | 11 | $176 |
| GSK | 9 | $158 |
| Novartis | 2 | $154 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $121 |
| Regeneron Healthcare Solutions, Inc. | 5 | $77 |
| Teva Pharmaceuticals USA, Inc. | 6 | $73 |
| Sanofi-aventis U.S. LLC | 5 | $66 |
| Biohaven Pharmaceuticals, Inc. | 3 | $50 |
| Abbott | 2 | $42 |
| Dexcom, Inc. | 2 | $39 |
| Merck | 2 | $39 |
| Lundbeck LLC | 2 | $39 |
| Exact Sciences | 2 | $37 |
| Harmony Biosciences LLC | 1 | $29 |
| Johnson & Johnson | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Bayer | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Upsher-smith Laboratories LLC | 1 | $18 |
| IBSA Pharma Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Optinose US, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| Vistapharm, Inc. | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,143 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $149,925 |
| MounjaroTirzepatide | 45 | $46,690 |
| JardianceEmpagliflozin | 34 | $45,490 |
| EliquisApixaban | 31 | $44,902 |
| RybelsusSemaglutide | 14 | $29,740 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $24,162 |
| EntrestoSacubitril/Valsartan | 19 | $23,611 |
| Repatha SureclickEvolocumab | 30 | $21,458 |
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $20,393 |
| XareltoRivaroxaban | 14 | $16,224 |
| VascepaIcosapent Ethyl | 20 | $12,490 |
| MyrbetriqMirabegron | 19 | $11,307 |
| FarxigaDapagliflozin Propanediol | 11 | $10,993 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $7,762 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $6,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,318 | $179,665129 claims |
| Boehringer IngelheimJardiance, Synjardy | $1,006 | $65,88346 claims |
| PfizerEliquis, Paxlovid | $176 | $47,63746 claims |
| Lilly USA, LLCMounjaro | $725 | $46,69045 claims |
| NovartisEntresto | $154 | $23,61119 claims |
| Johnson & JohnsonXarelto | $29 | $16,22414 claims |
| AstraZenecaFarxiga | $315 | $10,99311 claims |
| AbbVieLinzess | $456 | $6,30411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Huntsville
- Michael CarterHuntsville$3.4M
- Randle MiddletonHuntsville$3.3M
- Timothy HowardHuntsville$3M
- Edward WittHuntsville$321K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Jeffrey GarberHuntsville$87K
- Daniel EnglertHuntsville$82K
- Jack EnglertHuntsville$37K
- Tobin FisherHuntsville$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.